Clinical trial · Observational
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents
NCT01060098CI-TRIAL-00042823completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National Health Service) trusts will be recruited. We will correlate disease activity assessed by clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and target tissues, such as synovium and skin.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ankylosing Spondylitis | — | UNRESOLVED | — |
| Psoriatic Arthritis | — | UNRESOLVED | — |
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-TNF therapy (etanercept or adalimumab) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Rheumatoid arthritis
- description
- Participants with Rheumatoid arthritis
- interventionNames
- Drug: anti-TNF therapy (etanercept or adalimumab)
- label
- Ankylosing spondylitis
- description
- Participants with Ankylosing spondylitis
- interventionNames
- Drug: anti-TNF therapy (etanercept or adalimumab)
- label
- Psoriatic arthritis
- description
- Participants with Psoriatic arthritis
- interventionNames
- Drug: anti-TNF therapy (etanercept or adalimumab)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion criteria: * Only anti-TNF naïve patients will be included in this study * Patients between 18 to 80 years of age * Patients due to start treatment with anti-TNF blocking agents - etanercept or adalimumab Patients with rheumatoid arthritis * Only patients meeting the 1987 American College of Rheumatology (ACR) revised classification criteria for rheumatoid arthritis will be included * Patients should have active rheumatoid arthritis, defined by an initial DAS28 score \>5.1 * Patients should have at least 1 joint suitable for synovial biopsy * Patients can be on concurrent DMARDs but they should have been on a stable dose of DMARD for at least 1 month prior to study entry * Patients can be on a concurrent dose of glucocorticoids (up to 10mg daily) and they should have been on a stable dose for at least 4 weeks prior to study entry Patients with psoriatic arthritis * Patients should have a secure diagnosis of psoriatic arthritis determined by a rheumatologist * Patients with psoriatic arthritis included in this study should have evidence of concurrent psoriatic skin lesions at the time of study entry * Patients should have at least one joint suitable for synovial biopsy * Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry Patients with Ankylosing spondylitis * Patient should fulfil the Modified New York Criteria for diagnosis of ankylosing spondylitis * Patients can be on concurrent NSAIDs * Patients can be on concurrent DMARDs - they should be on a stable dose of DMARD for at least 1 month prior to study entry Exclusion Criteria: * Patients who have been previously treated with anti-TNF therapy for whatever reason * Patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who do not fulfil the diagnostic criteria for these conditions as above * Patient who have received an intra-articular injection of steroids or have received an intra-muscular injection of depot steroid to treat disease flare in the preceding 4 weeks prior to commencing anti-TNF therapy. * Patients with intercurrent, active infection of any type, excluding the common cold
References
Publications (2)
- RESULTHull DN, Cooksley H, Chokshi S, Williams RO, Abraham S, Taylor PC. Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Ther. 2016 Dec 23;18(1):303. doi: 10.1186/s13075-016-1197-5. PMID 28010726
- RESULTHull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015 Sep;181(3):401-6. doi: 10.1111/cei.12626. Epub 2015 Jun 23. PMID 25766640